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SUMMARY AT A GLANCE
For appropriately selected hemodialysis
(HD) patients, community based HD modality
seems to be a better treatment than
hospital based HD treatment in view of
Patient Enablement Instrument (PEI) and
Global Rating Scale (GRS) scores.
ABSTRACT:
Aim: Little is known about the effect of haemodialysis (HD) setting on out-
comes of patients with end stage renal disease (ESRD). The study aimed at
comparing clinical outcomes andpatient-reported outcomes (PRO) of patients
on community-based (CBHD) and hospital-based haemodialysis (HBHD).
Methods: A prospective cohort of Chinese ESRD patients receiving HBHD
(n=89) or CBHD (n=117) in Hong Kong were followed up for 12months. Sub-
jects were assessed on clinical outcomes of dialysis adequacy (Kt/V) and blood
haemoglobin and PRO of health-related quality of life (SF-12v2), general
health condition (Global Rating Scale (GRS)) and conﬁdence to copewith their
illness (Patient Enablement Instrument (PEI)). Differences between groups
were analyzed by independent t-tests for the SF-12v2, GRS and PEI scores. χ2
tests were used to analyze the difference in proportion of patients reaching
the targets of Kt/Vand blood haemoglobin andwith GRS> 0 and PEI>0.Mul-
tiple linear and logistic regressions were performed to assess the adjusted
difference-in-difference estimation.
Results: The mean PEI and GRS scores of CBHD patients at 12months were
signiﬁcantly higher than those of HBHD patients. CBHD patients had signiﬁ-
cantly greater improvement in self-efﬁcacy andweremore likely to be enabled
after 12months than the HBHD patients.
Conclusion: The study showed similar clinical outcomes and PRO between
CBHD and HBHD but CBHDwas more effective than HBHD in promoting pa-
tient enablement over a 12-month period. The results suggest added value for
patients receiving CBHDand support the transfer ofHD care from the hospital
to the community.
Over the past decade, a range of different approaches have
been developed to improve themanagement of care for people
with chronic illness. One of them is community-basedmanage-
ment, which adopts a patient-oriented approach to care. Trans-
ferring the care of stable patients with chronic disease into the
community allows patients to be close to their home or their
place of work saving time and improving the patient illness ex-
perience. Studies have demonstrated the value of community-
based care for patients with chronic disease, such as mental
health and diabetes.1,2 In chronic end stage renal disease, this
approach is supported by the ﬁndings of a systematic review
of observational studies, which showed that community-based
haemodialysis could provide quality of care comparable to or
even better than publicly funded hospital clinics.3,4 Moreover,
patients receiving community-based haemodialysis require less
medical attention compared with those receiving hospital-
based haemodialysis, therefore it is considered less costly.5
In Hong Kong, government policy mandates that patients
who require dialysis in the public sector receive peritoneal dial-
ysis as the ﬁrst line treatment unless there are contraindica-
tions.6 This policy accounts for the relatively low prevalence
of haemodialysis (HD) in Hong Kong compared with other de-
veloped countries. For example, in Hong Kong 23.8% of dialy-
sis patients receive HD7 comparedwith 40% inAustralia,8 76%
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in the UK9 and 95% in Japan.8 For those patients who are on
HD, most undergo the treatment in a renal unit of a
government-funded hospital.10 However, hospital-based HD
is resource-intensive and costly11 which encourages the explo-
ration of alternative models of service delivery. An example of
this is the shared-care, public-private partnershipmodel, which
was launched in Hong Kong in 2010. This haemodialysis
public-private partnership programme (HD-PPP), aimed to en-
hance the accessibility of HD for needy ESRD patients by pro-
viding the option of receiving HD in the community. Such a
community-based option would appear to have the beneﬁts
of accessibility, personalized care, continuity of care and other
environmental advantages but whether this setting affects pa-
tient outcomes compared with usual hospital-based HD has
not been systematically examined. This study therefore aims
to compare the longitudinal clinical and patient-reported out-
comes of HD patients in order to determine the effectiveness
of community-based HD in Hong Kong.
METHODS
Subjects and sampling
This was a longitudinal observational study. Subjects were
recruited between October 2012 and March 2013 from two
different settings distributed across Hong Kong1: Community-
based haemodialysis (CBHD) – patients receiving HD in the
community as part of the government-funded HD-PPP pro-
gramme and2 Hospital-based haemodialysis (HBHD) – patients
receiving HD as outpatients in government-funded hospitals.
All subjects in community-based HD centres of the HD-PPP
programme were recruited to join the study, while patients in
government-funded hospital-based HD units were recruited
by convenience sampling until a target sample size was
reached. Subjects from both settings were excluded if they
were aged <18years; could not understand Cantonese; had
cognitive impairment, refused to participate; or were too ill to
give consent. Trained research assistants explained the nature
of the study and invited subjects to participate. Those patients
who agreed to participate and who provided written consent
then completed a structured interviewer-administered ques-
tionnaire, which assessed patient-reported outcomes. The
health-related quality of life questionnaire was administered
at baseline and 12months while the patient enablement index
and global rating scale were administered at 12months only.
Setting
Community-based haemodialysis (CBHD)
The Haemodialysis Public Private Partnership (HD-PPP) is a
shared-care programme that gives eligible patients the option
of receiving HD treatment in the community but continue to
be followed up in the renal clinic of the public hospital. In this
service provision model, HD services are purchased from non-
government HD providers in the community without addi-
tional cost to the patient. In order to maintain the quality of
care of the HD service, the protocols for HD are standardized
across different community centres and care-providers receive
regular training. At each community HD centre, the nurse to
patient ratio is 1:5 which is much lower than that in public hos-
pitals. Nephrologists are generally not present on site but may
be called as needed. All patients receive regular follow up care
at the hospital renal clinic every 2–3 months. There were ﬁve
community-based HD centres, which provided HD services
for 124 patients under the HD-PPP programme during the
study period.
Hospital-based haemodialysis (HBHD)
Therewere 13 government-funded hospitals across HongKong
from which the HBHD patients were recruited. These hospitals
were chosen because they were the same hospitals providing
follow-up care to the CBHD patients. The number of patients
who receive HD as outpatients in hospitals ranges from 10 to
50 depending on the size of hospitals. At each hospital, the
nurse to patient ratio is 1:8 with nephrologists present on site.
Sample size calculation
A total of 115 patients from each group were needed to detect
the unadjusted difference-in-difference between CBHD and
HBHD at 12-month follow-up by independent t-test withmod-
erate effect size of 0.5 and 90% power at a signiﬁcance level of
0.05, assuming an attrition rate of 25%. All subjects in
community-based HD centres of the HD-PPP programme were
recruited to join the study, while patients in government-
funded hospital-based HD units were recruited by convenience
sampling until a target sample size was reached. Subjects from
both settings were excluded if they were aged<18years; could
not understand Cantonese; had cognitive impairment, refused
to participate; or were too ill to give consent. Trained research
assistants explained the nature of the study and invited subjects
to participate. Those patients who agreed to participate and
who provided written consent then completed a structured
interviewer-administered questionnaire.
Clinical outcome measures
The two criteria used as part of the evaluation of quality of care
for the HD-PPP programme in Hong Kong were adopted as the
clinical outcome measures for this study. The target standard
for dialysis adequacy measured by equilibrated, single pool or
on-line Kt/V was≥1.2 if patients were receiving three HD ses-
sions per week, ≥ 1.8 if receiving twice weekly HD or a total
weekly Kt/V≥ 3.6 (including dialysis and residual renal func-
tion). The target standard for blood haemoglobin was set
as≥9g/dL. These criteria and standardswere determined based
on international best practice and expert opinion.12
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Patient-reported outcome measures
The Short Form-12 version 2 (SF-12 v2) Health Survey
The Chinese (Hong Kong) SF-12 Health Survey is a frequently
used measure of Health-Related Quality of Life (HRQOL),
which has been validated and normed on the general Chinese
population in Hong Kong.13,14 It has been used to measure ge-
neric HRQOL in patients with diabetes, colorectal cancer, lower
urinary tract symptoms depression and end stage renal disease
undergoing haemodialysis in the local population.15–20 It mea-
sures eight domains of HRQOL namely physical functioning,
role physical, bodily pain, general health, vitality, social func-
tioning, role emotional and mental health on a scale with the-
oretical range from 0 to 100. A higher score indicates better
HRQOL. The eight domain scores are aggregated based on
population-speciﬁc weights to calculate two summary scores,
the physical (PCS) and mental component summary (MCS)
scores.
Patient enablement instrument (PEI)
The Patient Enablement Instrument (PEI) is a measure of pa-
tients’ understanding of and ability to cope with illness. It was
originally developed as a means of assessing the effectiveness
of a primary care consultation.21 The traditional Chinese ver-
sion of the PEI has been shown to be valid and reliable in
Chinese patients in Hong Kong.21,22 It consists of six items,
which enquires about the degree to which a patient is able to
(i) cope with life, (ii) understand their illness, (iii) cope with
their illness, (iv) keep themselves healthy, (v) be conﬁdent
about their health, and (vi) help themselves). Each item is rated
on a 3-point scale (0= the same or less; 1 = slightly improved/
increased; 2= greatly improved/increased). The summation of
six item scores provides the PEI score ranging from0 to 12, with
a higher score indicating better self-perceived enablement.
Subjects with PEI total score> 0 are considered to have
enablement over the past 12-month period, while those with
PEI total score=0were considered to have no enablement over
the period.
Global rating scale (GRS)
The Global Rating Scale (GRS) is a single retrospective item
assessing the subject’s global perception of any change in
his/her overall health condition on a 7-point scale (–3=much
worse to 3=much improved, with 0=no change) over a period
of 12months. The GRS has been used in longitudinal studies
evaluating changes in general health condition over time.23
Data analysis
Descriptive statistics were used to calculate the baseline charac-
teristics of socio-demographic and clinical data in the CBHD,
HBHD and the overall HD patients. Differences in baseline
characteristics between CBHD and HBHD patients were tested
by independent t-tests for continuous variables or χ2 tests for
categorical variables.
The within-subject changes in the SF-12 v2 PCS and MCS
between baseline and 12-month interview were analyzed by
paired t-tests. The unadjusted difference-in-difference in the
SF-12 v2 PCS andMCS scores between CBHD and HBHDwere
tested by independent t-tests. The differences in mean PEI and
GRS scores at 12-month interview between two groups were
analyzed by independent t-tests. χ2 tests were used to assess
the differences in proportions of reaching the targets of Kt/V
and blood haemoglobin, positive PEI (PEI>0) and GRS
(GRS> 0) between two groups. In addition, adjusted
difference-in-difference estimation between groups and the as-
sociation of target achievement of Kt/V, blood haemoglobin,
PEI and GRS at 12-months were assessed by multiple linear
and logistic regressions, respectively, adjusted by the confound-
ing factors including socio-demographics, clinical parameters
and comorbidities at baseline.
All statistical analysis was performed using STATA Version
13.0 (StataCorp LP, College Station, TX, USA). All signiﬁcance
tests were two-tailed and ﬁndings with a p-value less than
0.05 were considered statistically signiﬁcant.
RESULTS
A total of 124 subjects were enrolled into the HD-PPP pro-
gramme to receive HD in community-based centres and 110
subjects completed baseline face-to-face interviews. 181 sub-
jects who received HD in government-funded hospital based
HD centres were recruited and 134 completed baseline face-
to-face interviews. 89 (80.9%) CBHD and 117 (87.3%) HBHD
completed the 12-month follow-up interviews.
The socio-demographic and clinical characteristics of CBHD
and HBHD patients at baseline are displayed in Table 1. All of
the socio-demographics except working status and the trans-
portation used to dialysis centre between groups were similar.
More subjects in HBHD were in active employment, whereas
moreCBHDpatients travelled by public transport for HD. There
were no signiﬁcant differences in the proportions of subjects in
each group reaching the target levels of Kt/V and blood
haemoglobin. Moreover, both groups had similar proportions
of people suffering from common co-morbidities with the ex-
ceptions of diabetes mellitus and coronary heart disease. A
larger proportion of CBHD patients suffered from diabetes
mellitus while more HBHD patients suffered from coronary
heart disease.
Clinical outcomes
Table 2 shows the comparisons of Kt/V and blood haemoglobin
of CBHD and HBHD subjects at baseline and 12-months. There
were no statistical changes in the proportions reaching theKt/V
and blood haemoglobin targets between groups. Similarly no
association was found between setting and the achievement
Patient outcomes in hospital or community dialysis
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of target Kt/V or blood haemoglobin at 12-months after adjust-
ment for confounding factors (Table 3).
Patient-reported outcomes
Patient-reported outcomes of CBHD andHBHD subjects at baseline
and 12-months are demonstrated in Table 2. Paired t-tests foundno
statistical differences in SF-12 v2 PCS and MCS scores between
baseline and 12-months in both CBHD and HBHD patients.
Compared with HBHD patients, CBHD patients had higher PEI
(3.42 vs 1.79) and GRS (0.36 vs –0.37) scores at 12-months. More-
over, more patients in CBHD had increased enablement (85.4% vs
64.1%) and improved global health condition (46.1% vs 28.2%).
The results of adjusted difference-in-difference estimation of the
changes inPROat12-monthsbetweengroupsare showninTable4.
After adjusting for socio-demographic and co-morbidities, therewas
no signiﬁcant change in SF-12 v2 PCS and MCS between groups.
CBHD patients had signiﬁcantly greater improvement in self-
Table 1 Socio-demographic and clinical and co-morbidity information between community-based (CBHD) and hospital-based haemodialysis (HBHD) patients
Factor Total baseline
(n = 244)
CBHD patients HBHD patients P-value
Baseline (n = 110) Baseline (n = 134)
Socio-demographic
Sex 0.757
Female 40.16% (98) 39.09% (43) 41.04% (55)
Male 59.84% (146) 60.91% (67) 58.96% (79)
Age (mean ± SD), year 56.59 ± 12.69 57.25 ± 13.03 56.04 ± 12.43 0.463
Educational level 0.696
No formal education 8.61% (21) 10.00% (11) 7.46% (10)
Primary 27.05% (66) 23.64% (26) 29.85% (40)
Secondary 53.69% (131) 55.45% (61) 52.24% (70)
Tertiary 10.66% (26) 10.91% (12) 10.45% (14)
Marital status 0.583
Unmarried 34.57% (84) 32.73% (36) 36.09% (48)
Married 65.43% (159) 67.27% (74) 63.91% (85)
Smoking status 0.152
Non-smoker 95.08% (232) 97.27% (107) 93.28% (125)
Current smoker 4.92% (12) 2.73% (3) 6.72% (9)
Come alone/accompanied for HD session 0.494
Alone 83.61% (204) 81.82% (90) 85.07% (114)
Accompanied by others 16.39% (40) 18.18% (20) 14.93% (20)
Transportation 0.024*
Walk 8.20% (20) 8.18% (9) 8.21% (11)
Public transport 74.59% (182) 81.82% (90) 68.66% (92)
Taxi/ Others 17.21% (42) 10.00% (11) 23.13% (31)
Working status 0.011*
Not working 79.10% (193) 86.36% (95) 73.13% (98)
Working 20.90% (51) 13.64% (15) 26.87% (36)
Clinical and Co-morbidity Information †
Baseline Kt/V 0.337
Target‡ not achieved 26.76% (57) 29.63% (32) 23.81% (25)
Target‡ achieved 73.24% (156) 70.37% (76) 76.19% (80)
Baseline blood haemoglobin (mean ± SD), g/dL 10.38 ± 1.74 10.51 ± 1.72 10.26 ± 1.76 0.280
Baseline blood haemoglobin 0.184
Target not achieved (<9 g/dL) 23.29% (51) 19.44% (21) 27.03% (30)
Target achieved (≥9 g/dL) 76.71% (168) 80.56% (87) 72.97% (81)
Co-morbidities
Diabetes mellitus 28.77% (63) 35.19% (38) 22.52% (25) 0.038*
Hypertension 68.04% (149) 66.67% (72) 69.37% (77) 0.668
Coronary heart disease 20.55% (45) 14.81% (16) 26.13% (29) 0.038*
Stroke 3.65% (8) 5.56% (6) 1.80% (2) 0.139
Heart failure 13.24% (29) 11.11% (12) 15.32% (17) 0.359
Psychological condition 4.11% (9) 6.48% (7) 1.80% (2) 0.081
Number of co-morbidities (mean ± SD) 1.38 ± 1.15 1.40 ± 1.13 1.37 ± 1.18 0.854
Notes: *Signiﬁcant with P-value< 0.05 by χ2 square test or t-test as appropriate †2 of the CBHD patients and 23 of the HBHD patients are excluded in the analysis as
their ID cannot be linked with the HA dataset ‡Target: Kt/V ≥ 1.8 for 2 HD sessions per week or Kt/V ≥ 1.2 for 3 HD sessions per week or Kt/V ≥ 3.6 for weekly data
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efﬁcacy and global health condition after 12months (PEI: Coeff.
=1.593, P<0.001; GRS: Coeff.=0.597, P=0.016) than HBHD pa-
tients. Table 3 also illustrates that CBHD patients were generally
more likely to become enabled (OR =2.705, P=0.022) after
12months than the HBHD patients. CBHD patients were also
more likely to improve global health condition after 12months
compared with HBHD patients but this was not statistically
signiﬁcant (OR =1.576, P=0.214).
DISCUSSION
We note that the CBHD group were mostly a self-selected
group and therefore should already be motivated, fairly
independent and in relatively better health, which might
suggest that they were in a more advantageous position to
do well. That more CBHD patients took public transit and a
signiﬁcantly lower proportion of CBHD patients had coro-
nary heart disease compared with the HBHD group support
this. However, it was surprising that in the CBHD group,
the proportions of patients with diabetes and not working
were signiﬁcantly higher than that in the HBHD group,
which may suggest the opposite, i.e. relatively poorer health.
The reason for this is not clear but additional data on dura-
tion or severity of the comorbid condition and household in-
come would help to clarify the actual health condition of the
CBHD group as well as to determine whether not working
was due to choice rather than poor health. There was no sig-
niﬁcance difference between groups in other demographic
Table 2 Comparisons of Kt/V, blood haemoglobin, SF-12 v2, PEI score and GRS between community-based (CBHD) and hospital-based haemodialysis (HBHD) patients






Kt/V target§ achieved 75.86% 78.16% 79.17% 78.49% 2.98%
Diff. = 2.30% P = 0.719 Diff. = –0.68% P = 0.910
Blood haemoglobin
target¶ achieved
82.76% 85.06% 72.73% 79.38% –4.35%
Diff. = 2.30% P = 0.680 Diff. = 6.65% P = 0.275
PCS 45.63 ± 11.14 43.78 ± 10.68 40.01 ± 10.89 37.96 ± 12.61 0.20
Paired diff. = –1.85 ± 10.10 P = 0.957 Paired diff. = –2.05 ± 12.38 P = 0.962
MCS 55.24 ± 8.44 55.80 ± 10.38 53.72 ± 9.98 53.01 ± 11.45 1.27
Paired diff. = 0.56 ± 9.39 P = 0.286 Paired diff. = –0.71 ± 13.76 P = 0.710
PEI NA 3.42 ± 2.63 NA 1.79 ± 2.10 1.63*
85.39%† 64.10%† 21.29%*
GRS NA 0.36 ± 1.40 NA -0.37 ± 1.52 0.73*
46.07%‡ 28.21%‡ 17.86%*
GRS, Global Rating Scale (Range scale: –3–3); MCS, Mental Component Summary Score (Range scale: 0–100); NA: Not applicable; PCS, Physical Component Summary
Score (Range scale: 0–100); PEI, Patient Enablement Instrument (Range scale: 0–12). Notes: *Signiﬁcant with P-value< 0.05 by χ2 test or t-test as appropriate †PEI> 0
‡GRS> 0 §Target: Kt/V ≥ 1.8 for 2 HD sessions per week or Kt/V ≥ 1.2 for 3 HD sessions per week or Kt/V ≥ 3.6 for weekly data ¶Target: blood haemoglobin ≥ 9 g/dL
Table 3 Effectiveness of haemodialysis public-private partnership programme
(HD-PPP) associated with changes in SF-12 v2, PEI score and GRS at 12months





Coeff. 95% CI P-value
Model 1: Change‡
in PCS (n = 183)
3.372 (–0.086, 6.830) 0.056
Model 2: Change‡
in MCS (n = 183)
1.470 (–1.937, 4.877) 0.395
Model 3: PEI score
at 12-month (n = 183)
1.511* (0.737, 2.286) <0.001*
Model 4: GRS at
12-month (n = 183)
0.597* (0.114, 1.081) 0.016*
CI, Conﬁdence Interval; Coeff, Coefﬁcient; GRS, Global Rating Scale (Range scale:
–3–3); MCS, Mental Component Summary Score (Range scale: 0–100); PCS,
Physical Component Summary Score (Range scale: 0–100); PEI, Patient
Enablement Instrument (Range scale: 0–12). All models are adjusted by baseline
socio-demographic and clinical and co-morbidity information Notes: *Signiﬁcant
with P-value< 0.05 †HBHDpatients (Control) are the reference level for the com-
parison between groups ‡Change means 12-month – baseline
Table 4 Effectiveness of haemodialysis public-private partnership programme
(HD-PPP) associated with target achievement of Kt/V, blood haemoglobin, PEI
score and GRS at 12months by multivariable logistic regressions
Multivariate logistic regressions Independent variables
CBHD patients†
OR 95% CI P-value
Model 1: Kt/V target‡ achieved
at 12-month (n = 179)
1.081 (0.427,2.739) 0.869
Model 2: Blood haemoglobin target§
achieved at 12-month (n = 183)
1.161 (0.402,3.351) 0.783
Model 3: PEI> 0 at 12-month (n = 183) 2.705* (1.158,6.321) 0.022*
Model 4: GRS> 0 at 12-month (n = 183) 1.576 (0.769,3.231) 0.214
CI, Conﬁdence Interval; GRS, Global Rating Scale (Range scale: –3–3); OR, Odds
Ratio; PEI, Patient Enablement Instrument (Range scale: 0–12).All models are ad-
justed by baseline socio-demographic and clinical and co-morbidity information
Notes: *Signiﬁcant with P-value< 0.05 †HBHD patients (Control) are the refer-
ence level for the comparison between groups ‡Target: Kt/V ≥ 1.8 for 2 HD ses-
sions per week or Kt/V> 1.2 for 3 HD sessions per week or Kt/V ≥ 3.6 for weekly
data §Target: blood haemoglobin ≥ 9 g/dL
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and background features or comorbidities such as hyperten-
sion, stroke and heart failure, which implied that the groups
were otherwise similar.
Clinical outcomes
Community-based HD patients achieved dialysis adequacy and
blood haemoglobin levels comparable with that achieved by
patients undergoing HBHD. This result was expected as the ser-
vice provision procedures and setting requirements for HD
treatment were standardized between hospital and community
HD centre and overseen by regular review and audit. More-
over, as the community HD centres also offer private HD ser-
vices concurrently with the HD-PPP programme, they have a
vested interest in maintaining high quality of care and stan-
dards of service in order to remain competitive. Moreover,
these ﬁndings are consistent with previous studies in which
the clinical outcomes of haemodialysis treatment in the com-
munity were found to be at least equivalent to those achieved
in the hospital setting.24,25
Patient-reported outcomes – health-related quality of life
Previous longitudinal studies of HD patients found that the
mental aspect of health-related quality of life remained con-
stant while the physical component declined.26–28 This was dif-
ferent from our study where neither the physical nor the
mental summary scores (PCS and MCS) of the SF-12v2
changed over time. A possible explanation for why the study
subjects in both groups perceived no change in physical
health-related quality of life may be due to freedom of choice
in selecting the HD setting, which suited their physical needs.
Those who attended the CBHD were usually more indepen-
dentlymobile and chose the CBHD setting because of easy geo-
graphical accessibility, which is consistent with previous
ﬁndings which associated longer travelling time to dialysis cen-
tres with lower quality of life.29 Similarly, HBHD patients chose
to remain in the hospital setting because they felt their needs
were already well looked after and indicated to interviewers
that they were satisﬁed with the setting and the care and did
not wish tomove. Being satisﬁedwith caremay have a positive
relationship with health-related quality of life.30 On the other
hand, it is also possible that the duration of the follow up was
too short to detect meaningful changes in HRQOL or that the
SF-12 v2 instrument, being a genericmeasure, might not be re-
sponsive enough to capture the change of HRQOL in HD
patients. Further study with the use of both generic and
disease-speciﬁc measures would be useful to evaluate the
HRQOL of HD patients for a longer period of time.
Patient-reported outcomes – enablement and global health
condition
At the 12-month interview, more CBHD patients reported in-
creased enablement and improved general health condition
compared with HBHD patients. With a lower nurse to patient
ratio in community HD centre compared with the renal unit
of hospital (5:1 compared with 8:1) the possibilities for patient
empowerment are greater in the CBHD setting. The lower
nursing ratio can allow a nurse to spend more time with pa-
tients in order to provide more in-depth, personalized patient
care including providing additional education and opportunity
for self-care. For example, in some community HD centres,
there were interactive education sessions run during the dialy-
sis session, which taught patients different exercises that could
be done during dialysis treatment. As well, patients were given
the responsibility of measuring their own body weight, setting
up their own dialysis station at the start of each session. The ef-
fort to encourage patients to take an active role in their chronic
disease management may have led to the enhancement in pa-
tients’ conﬁdence and ability to cope observed in this setting.
This sense of empowerment could lead to better perception of
their own general health condition.19
However, after adjusting for background factors, the pa-
tients’ perception of general health condition remained con-
stant which may be because incomplete cases were excluded
in the adjusted analysis. Among the incomplete cases, nearly
three-quarters of HBHD patients did not improve in global
health condition, which may inﬂuence the conclusion. Further
study would be needed to conﬁrm the improvement of global
health condition for the CBHD patients.
Limitations of this study
There were a number of limitations to this study. Firstly, all
subjects were recruited from the public sector and the results
may not be generalizable to Chinese patients receiving HD in
the private sector. In addition, the CBHD were mostly a self-
selected group with some inherent differences compared with
the HBHD group, such as functional independence and health
status. Second, the follow-up period was only 12months and
only two clinical outcomes measures were evaluated. A longer
follow-up period and a more comprehensive complement of
clinical outcome indicators could be captured, to enable a more
thorough evaluation of the impact of CBHD in this context.
Third, as this was an observational study, the effect of HD set-
ting on outcomes could be biased and a randomized controlled
trial would be needed to explore more deﬁnitively any differ-
ences in effectiveness between CBHD and HBHD.
CONCLUSIONS
The study showed that community-based and hospital-based
HD achieved similar clinical outcomes with an additional bene-
ﬁt of better patient enablement for subjects undergoing CBHD.
The advantages conferred by the community setting appear to
translate to a higher level of conﬁdence in coping among these
HD subjects and supports the transfer of HD care from the hos-
pital to the community. Further studies are needed to evaluate
JY Chen et al.
© 2015 The Authors Nephrology published by Wiley Publishing Asia Pty Ltd on behalf of Asian Paciﬁc Society of Nephrology622
long-term effectiveness and the change of HRQOL of CBHD
subjects.
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